托珠单抗在一名细胞因子释放综合征的COVID-19患者中的疗效
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.
作者信息
Uslu Sadettin
机构信息
Department of Rheumatology, Ömer Halisdemir University Bor Physical Medicine and Rehabilitation, Training and Research Hospital, Niğde, Turkey.
出版信息
Eur J Case Rep Intern Med. 2020 May 22;7(6):001731. doi: 10.12890/2020_001731. eCollection 2020.
UNLABELLED
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.
LEARNING POINTS
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by COVID-19.CRS can be life-threatening in severe COVID-19.Tocilizumab may have a role in treating severe COVID-19 patients with CRS.
未标注
细胞因子释放综合征（CRS）是一种全身性炎症反应，可由多种因素触发，如感染。2019冠状病毒病（COVID-19）患者的CRS危及生命，且在COVID-19诊断后可能很快发生。托珠单抗（TCZ）是一种白细胞介素-6（IL-6）抑制剂，可能改善与重症COVID-19相关的CRS，从而改善临床结局。我们报告一例由COVID-19感染引起的危及生命的CRS病例，经TCZ成功治疗。
学习要点
细胞因子释放综合征（CRS）是一种可由COVID-19触发的全身性炎症反应。CRS在重症COVID-19中可能危及生命。托珠单抗可能在治疗患有CRS的重症COVID-19患者中发挥作用。
Zotero 插件